A retrospective study was performed to assess the outcomes of a single-fraction adjuvant electronic brachytherapy (e-BT) approach for patients with squamous cell conjunctival carcinoma (SCCC). Forty-seven patients with T1-T3 SCCC were included. All patients underwent surgery followed by a single-fraction adjuvant e-BT with a porTable 50-kV device. Depending on margins, e-BT doses ranged between 18 to 22 Gy prescribed at 2 mm depth, resembling equivalent doses in 2 Gy (EQD2) per fraction of 46-66 Gy (α/β ratio of 8-10 Gy and a relative biological effect (RBE) of 1.3). The median age was 69 (29-87) years. Most tumors were T1 (40.4%) or T2 (57.5%) with a median size of 7 mm (1.5-20). Margins were positive in 40.4% of cases. The median time from surgery to e-BT was nine weeks (0-37). After a median follow-up of 24 (17-40) months, recurrence occurred in only two patients (6 and 7 months after e-BT), yielding a median disease-free survival (DFS) of 24 (6-40) months and DFS at two years of 95.7%. Acute grade 2 conjunctivitis occurred in 25.5%. E-BT is a safe and effective for SCCC treatment, with clinical and logistic advantages compared to classical methods. Longer follow-up and prospective assessment are warranted.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865874 | PMC |
http://dx.doi.org/10.3390/cancers13030454 | DOI Listing |
Neurosurg Rev
November 2024
Department of Neurosurgery, Koç University School of Medicine, Türkiye Davutpasa Caddesi No:4, Istanbul, Zeytinburnu/İstanbul, 34010, Turkey.
While single-fraction Gamma Knife radiosurgery (GKRS) has shown efficacy in managing vestibular schwannomas (VSs), some concerns have been raised regarding its safety profile, particularly in the context of hearing preservation. Hypofractionation has emerged as a promising approach to improving the safety profile. This retrospective, single-institution study evaluated patient outcomes following hypofractionated GKRS (hf-GKRS) for treatment-naïve Koos grade IV VSs.
View Article and Find Full Text PDFJ Neurosurg Case Lessons
November 2024
Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota.
Background: The management of cystic brain metastases remains challenging, with high recurrence rates following treatment with resection and/or stereotactic radiosurgery (SRS). Tumor resection and adjuvant radiation provide superior outcomes in comparison to those for each therapy alone, but large cystic tumor en bloc removal is difficult. Cyst aspiration can be used to decrease the radiation target volume, enabling safer delivery of a therapeutic radiation dose with improved local tumor control.
View Article and Find Full Text PDFNeuro Oncol
November 2024
Department of Radiological Sciences, Oncology, and Anatomical Pathology, Sapienza University of Rome, Rome, Italy.
Front Oncol
October 2024
Department of General Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Background: Intraoperative radiation therapy (IORT) and whole breast irradiation (WBI) are both effective adjuvant radiotherapy methods for ductal carcinoma (DCIS) or early-stage breast cancer (BC) patients undergoing breast-conserving surgery (BCS). We aim to evaluate the long-term oncological efficacy and refine patient selection criteria based on our findings.
Methods: Female patients who underwent either IORT or WBI from January 2016 to December 2019, with a minimum follow-up of 12 months were collected.
J Neurooncol
December 2024
Department of Neurological Surgery, University of Pittsburgh Medical Center, 200 Lothrop St Suite B-400, Pittsburgh, PA, 15213, USA.
Purpose: Spinal metastases may result in intractable pain, neurological deficit, and vertebral body collapse. There are only a few studies describing outcomes following spine stereotactic radiosurgery (SRS) specifically for prostate cancer metastases.
Methods: A prospectively collected database of patients with prostate cancer spinal metastases treated at the University of Pittsburgh Medical Center from 2003 to 2023 was analyzed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!